PubRank

Brian Calingaert

Author PubWeight™ 52.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005 3.31
2 Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013 2.15
3 Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 2006 1.75
4 Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev 2008 1.73
5 Racial differences in enrolment in a cancer genetics registry. Cancer Epidemiol Biomarkers Prev 2004 1.62
6 Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2009 1.59
7 Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol 2003 1.55
8 The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. Gynecol Oncol 2009 1.54
9 Topiramate use in pregnancy and the birth prevalence of oral clefts. Pharmacoepidemiol Drug Saf 2014 1.52
10 Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012 1.50
11 Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 2008 1.46
12 Analgesic drug use and risk of ovarian cancer. Epidemiology 2006 1.33
13 Folic acid supplementation before and during pregnancy in the Newborn Epigenetics STudy (NEST). BMC Public Health 2011 1.29
14 Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002 1.29
15 The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol 2007 1.24
16 Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011 1.21
17 Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. Clin Cancer Res 2003 1.19
18 Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control 2002 1.14
19 Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007 1.14
20 The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord 2014 1.08
21 Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women. Cancer Causes Control 2005 1.08
22 Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test 2002 1.04
23 Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol Oncol 2005 1.02
24 Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol 2008 1.00
25 Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev 2004 0.98
26 High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res 2003 0.97
27 Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 2007 0.97
28 Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecol Oncol 2004 0.93
29 The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol 2006 0.91
30 Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol 2007 0.91
31 Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 2005 0.89
32 Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol Biomarkers Prev 2008 0.89
33 Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. J Soc Gynecol Investig 2003 0.87
34 No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. Cancer Epidemiol Biomarkers Prev 2003 0.86
35 Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 2012 0.84
36 Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecol Oncol 2005 0.83
37 Prospective and longitudinal patient self-assessment of health-related quality of life following radical perineal prostatectomy. J Urol 2004 0.82
38 Use of long-acting beta-agonists and inhaled steroids in asthma: meta-analysis of observational studies. J Asthma 2010 0.81
39 Antidepressant medication use [corrected] and risk of ovarian cancer. Obstet Gynecol 2005 0.80
40 Maternal outcomes among pregnant women receiving live attenuated influenza vaccine. Influenza Other Respir Viruses 2011 0.79
41 Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists. Int J Gynecol Cancer 2009 0.79
42 Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin. Endocr Pract 2011 0.79
43 IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. Int J Cancer 2009 0.78
44 Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial users. Curr Drug Saf 2014 0.78
45 Topiramate use during pregnancy and major congenital malformations in multiple populations. Birth Defects Res A Clin Mol Teratol 2015 0.77
46 Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study. Pharmacotherapy 2013 0.76